Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.33 USD
-0.08 (-1.48%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.43 +0.10 (1.88%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAPR 5.33 -0.08(-1.48%)
Will CAPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
Other News for CAPR
Capricor Therapeutics Updates on Duchenne Treatment Progress
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements
Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy